(Q40359028)

English

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer

scientific article published on 10 May 2010

Statements

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer (English)
S Gail Eckhardt
Scot Ebbinghaus
Peter J O'Dwyer
Michael S Gordon
William Novotny
Meredith A Goldwasser
Tanyifor M Tohnya
David S Mendelson

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit